View in EDS HTML Full Text PDF Full Text

Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition.

Saved in:
Bibliographic Details
Title: Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition.
Authors: Kam NW; LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.; School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China., Lau JYH; LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China., Lau CY; LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.; School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China., Lam TC; Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China., Chan KSK; LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China., Dai W; Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China., Fun VLH; Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China., Chiang CL; Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China., Kwong DLW; Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Source: Clinical and translational medicine [Clin Transl Med] 2025 Nov; Vol. 15 (11), pp. e70535.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101597971 Publication Model: Print Cited Medium: Internet ISSN: 2001-1326 (Electronic) Linking ISSN: 20011326 NLM ISO Abbreviation: Clin Transl Med Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41263637
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kam+NW%22">Kam NW</searchLink>; LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.; School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Lau+JYH%22">Lau JYH</searchLink>; LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Lau+CY%22">Lau CY</searchLink>; LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.; School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Lam+TC%22">Lam TC</searchLink>; Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Chan+KSK%22">Chan KSK</searchLink>; LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Dai+W%22">Dai W</searchLink>; Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Fun+VLH%22">Fun VLH</searchLink>; Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Chiang+CL%22">Chiang CL</searchLink>; Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Kwong+DLW%22">Kwong DLW</searchLink>; Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101597971%22">Clinical and translational medicine</searchLink> [Clin Transl Med] 2025 Nov; Vol. 15 (11), pp. e70535.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101597971 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2001-1326 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220011326%22">20011326 </searchLink><i>NLM ISO Abbreviation: </i>Clin Transl Med <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41263637
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/ctm2.70535
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e70535
    Titles:
      – TitleFull: Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kam NW
      – PersonEntity:
          Name:
            NameFull: Lau JYH
      – PersonEntity:
          Name:
            NameFull: Lau CY
      – PersonEntity:
          Name:
            NameFull: Lam TC
      – PersonEntity:
          Name:
            NameFull: Chan KSK
      – PersonEntity:
          Name:
            NameFull: Dai W
      – PersonEntity:
          Name:
            NameFull: Fun VLH
      – PersonEntity:
          Name:
            NameFull: Chiang CL
      – PersonEntity:
          Name:
            NameFull: Kwong DLW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2025 Nov
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2001-1326
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Clinical and translational medicine
              Type: main
ResultId 1